Candel Therapeutics, Inc. filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on September 9, 2026. The filing includes an investor presentation titled "Tipping the balance in favor of the immune system to fight cancer," which outlines the company's corporate strategy and financial status.
The presentation highlights the company's two primary therapeutic platforms: the adenovirus platform and the herpes simplex virus (HSV) platform. The lead candidate, aglatimagene besadenovec (CAN-2409), is described as an off-the-shelf pan-solid tumor therapy. The company notes that a randomized phase 3 clinical trial in localized, intermediate- to high-risk prostate cancer achieved the primary endpoint of disease-free survival. Additionally, the company reports positive overall survival data from randomized phase 2a clinical trials in borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer.
Regarding regulatory status, aglatimagene has received an FDA Regenerative Medicine Advanced Therapy (RMAT) designation for prostate cancer, as well as Fast Track Designations for non-small cell lung cancer, pancreatic cancer, and prostate cancer. It also holds Orphan Drug Designation for pancreatic cancer. The company’s second candidate, linoserpaturev (CAN-3110), is an oncolytic HSV-1 designed for tumor-specific replication. The presentation cites proof of concept in patients with recurrent high-grade glioma and notes the candidate has received Fast Track and Orphan Drug Designations for this indication.
Financially, the company reports cash and cash equivalents of $201.6 million as of June 30, 2026. The company states this provides an expected runway into the first quarter of 2028. The filing also details recent financing activities, including a term loan facility with Trinity Capital entered into in October 2025 and a $100 million royalty funding agreement with RTW Investments entered into in February 2026, subject to the approval of aglatimagene in localized prostate cancer.
